MAPK14 and non-small cell lung carcinoma: Herein, the results showed the active-p38 significantly increased in a dose dependent manner of gefitinib (0–20 μM) treatment in IEC-18 cell by Western blotting (Figure 7B), but not in the NSCLC cell lines (data not shown).